Goldman Sachs Reiterates Neutral Rating on Edwards Lifesciences (EW)

Goldman Sachs is out with a research report this morning, where it reiterates its Neutral rating on Edwards Lifesciences Corp.

; it has a $76.00 price target on the stock. The GS analysts cited the company's recently announced quarterly earnings report, which misses the Street's estimates due to lower segment sales across all businesses. The analysts said that they are maintaining the Neutral rating given what they continue to view as balanced risk/reward at current levels. They said, “With the stock remaining close to peak levels post positive data presented at TCT, we are hesitant to get more constructive on the name, given valuation. Near term, we see little to derail the company's progress in the TCV business in Europe, as Medtronic looks to be falling further behind in market share.”